Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SUVN-911 in Healthy Men
NCT03155503Phase 1Completed
- Sponsor
- Suven Life Sciences
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ropanicant in major depressive disorder (MDD) (2 arms), sponsored by Suven Life Sciences. Primary endpoints: Electrocardiogram, Vital signs and 1 more. Started May 2017; status: completed.
02
Drugs
Ropanicant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03155503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155503.